March 2024, New poster is released by the Fungicide Resistance Action Committee (FRAC), revealing the inclusion of Group 54, Benzoxaboroles, in the…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Tag:
NOVARTIS
-
-
Merger / Acquisition
Alcon Expands Foothold in Eye Sector with $770 Million Aerie Pharmaceuticals Purchase
by adminby adminIn order to gain access to Aerie Pharmaceuticals’ open-angle glaucoma and ocular hypertension medications, Alcon announced that it will acquire the company…
-
CompaniesIndiaMerger / AcquisitionNovartis
Dr. Reddy’s will Pay Rs 463 Crore for Novartis’ Cardiovascular Drug Cidmus (Valsartan +Sacubitril)
by adminby adminSummary Dr Reddy’s Laboratories, an Indian generic pharmaceutical company, has agreed to pay $61 million to Novartis AG for the cardiovascular brand…
-
Global Market
AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war
by adminby adminSummary : Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli…
-
CompaniesNovartis
Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
by adminby adminSummary : Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER…
-
CompaniesGlobal MarketNovartis
Syncona announces sale of portfolio company to Novartis
by adminby adminSynopsis : Syncona – a company focused on founding, building and funding global leaders in life science – has announced the sale…
-
-
CompaniesGlobal MarketNovartis
Financials Indicate Novartis’ Sandoz Division Could Be a Tough Sell
by adminby adminSynopsis : Novartis reported its full-year financials this week for 2021, and overall, the news was good. Full-year net sales grew 4%,…
-
CompaniesGlobal MarketNovartis
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
by adminby adminSynopsis : Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep,…
-
CompaniesGlobal MarketNovartis
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent.
by adminby adminSynopsis: -Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US…
Newer Posts